• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    2/29/24 4:31:36 PM ET
    $BMRA
    $BNR
    $CDXS
    $CRDF
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical Specialities
    Health Care
    Get the next $BMRA alert in real time by email

    Gainers

    • Cardiff Oncology (NASDAQ:CRDF) shares moved upwards by 28.6% to $2.27 during Thursday's after-market session. The company's market cap stands at $101.4 million. As per the press release, Q4 earnings came out today.
    • Kineta (NASDAQ:KA) shares increased by 20.6% to $0.99. The market value of their outstanding shares is at $10.2 million.
    • Burning Rock Biotech (NASDAQ:BNR) stock rose 10.84% to $0.88. The market value of their outstanding shares is at $90.3 million.
    • Y-mAbs Therapeutics (NASDAQ:YMAB) shares moved upwards by 8.68% to $18.15. The market value of their outstanding shares is at $791.7 million. The company's, Q4 earnings came out today.
    • Lucy Scientific Discovery (NASDAQ:LSDI) stock increased by 7.58% to $1.84. The company's market cap stands at $3.2 million.
    • Xilio Therapeutics (NASDAQ:XLO) shares rose 6.98% to $0.76. The market value of their outstanding shares is at $20.8 million.

    Losers

    • Gritstone Bio (NASDAQ:GRTS) shares decreased by 25.4% to $2.09 during Thursday's after-market session. The company's market cap stands at $199.2 million.
    • Humacyte (NASDAQ:HUMA) stock declined by 20.52% to $3.44. The company's market cap stands at $356.4 million.
    • Cue Health (NASDAQ:HLTH) stock decreased by 14.07% to $0.28. The company's market cap stands at $42.5 million.
    • Precision BioSciences (NASDAQ:DTIL) shares fell 10.82% to $16.5. The company's market cap stands at $67.0 million.
    • Biomerica (NASDAQ:BMRA) stock fell 9.02% to $1.11. The company's market cap stands at $18.6 million.
    • Codexis (NASDAQ:CDXS) shares fell 8.61% to $4.25. The market value of their outstanding shares is at $296.7 million. The company's, Q4 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BMRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BMRA
    $BNR
    $CDXS
    $CRDF

    CompanyDatePrice TargetRatingAnalyst
    Cardiff Oncology Inc.
    $CRDF
    1/5/2026$12.00Outperform
    Noble Capital Markets
    Humacyte Inc.
    $HUMA
    8/27/2025$3.50Overweight
    Barclays
    Xilio Therapeutics Inc.
    $XLO
    8/6/2025$2.00Outperform
    Leerink Partners
    Cardiff Oncology Inc.
    $CRDF
    7/8/2025$19.00Buy
    Ladenburg Thalmann
    Cardiff Oncology Inc.
    $CRDF
    6/24/2025$3.50Hold
    Jefferies
    Humacyte Inc.
    $HUMA
    5/14/2025$4.00Buy
    H.C. Wainwright
    Y-mAbs Therapeutics Inc.
    $YMAB
    4/22/2025$3.00Neutral → Underperform
    BofA Securities
    Precision BioSciences Inc.
    $DTIL
    1/10/2025$34.00Market Perform → Outperform
    BMO Capital Markets
    More analyst ratings

    $BMRA
    $BNR
    $CDXS
    $CRDF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Germano Geno J bought $14,160 worth of shares (3,000 units at $4.72), increasing direct ownership by 14% to 23,883 units (SEC Form 4)

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    12/17/25 7:02:05 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Frankel Stanley bought $12,690 worth of shares (2,700 units at $4.70), increasing direct ownership by 16% to 19,478 units (SEC Form 4)

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    12/17/25 7:01:09 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Brown Melinda bought $6,864 worth of shares (1,381 units at $4.97), increasing direct ownership by 6% to 23,346 units (SEC Form 4)

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    12/17/25 7:00:53 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMRA
    $BNR
    $CDXS
    $CRDF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Mohindru Mani

    4 - Cardiff Oncology, Inc. (0001213037) (Issuer)

    4/2/26 4:16:32 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Han Yusheng

    4 - Burning Rock Biotech Ltd (0001792267) (Issuer)

    4/2/26 7:17:47 AM ET
    $BNR
    Medical Specialities
    Health Care

    SEC Form 4 filed by Shannon James Samuel

    4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)

    3/30/26 5:29:01 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRA
    $BNR
    $CDXS
    $CRDF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for DANYELZA issued to Y-MABS THERAPEUTICS INC

    Submission status for Y-MABS THERAPEUTICS INC's drug DANYELZA (SUPPL-8) with active ingredient NAXITAMAB-GQGK has changed to 'Approval' on 03/20/2024. Application Category: BLA, Application Number: 761171, Application Classification:

    3/21/24 10:20:07 AM ET
    $YMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 6, 2023 - FDA Permits Marketing of First COVID-19 At-Home Test Using Traditional Premarket Review Process

    For Immediate Release: June 06, 2023 Today, the U.S. Food and Drug Administration granted marketing authorization for the Cue COVID-19 Molecular Test. The product is a molecular nucleic acid amplification test (NAAT) that is intended to detect genetic material from SARS-CoV-2 virus present in nasal swabs from adults with signs and symptoms of upper respiratory infection. This test is the first at-home over-the-c

    6/6/23 3:04:14 PM ET
    $HLTH
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BMRA
    $BNR
    $CDXS
    $CRDF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective April 1, 2026, the company granted non-qualified stock options to purchase 3,257 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan. The stock options have an exercise price of $8.48 per share, which is equal to the closing price of the company's common stock on April 1, 2026. Each stock option has a ten-year term and will vest as to 25% of the shares underlying the stock option on

    4/3/26 4:30:00 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Burning Rock Announces Founder's Purchase of Its ADSs

    GUANGZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock")), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that its founder, chairman of the board of directors and chief executive officer, Mr. Yusheng Han, has purchased 31,487 of the Company's ADSs for US$546,603.90 from the open market, which was conducted in compliance with the applicable rules and regulations and the Company's insider trading policy. As of the date of this press release, combined with 41,246 ADSs purchased in the last post-earnings trading window, Mr. Han has pur

    4/2/26 6:25:59 AM ET
    $BNR
    Medical Specialities
    Health Care

    Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

    - Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year -  - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and outreach program in the Kingdom of Saudi Arabia - - Submitted of a Marketing Authorization Application with the Israel Ministry of Health - - U.S. Department of Defense authorized funding for procurement of bioengineered blood vessels - - Major milestone upcoming: Top-line interim result from V012 Phase 3 study in hemodialysis access - - Conference call today at 8:00 am ET - DURHAM, N.C., March 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a c

    3/27/26 7:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMRA
    $BNR
    $CDXS
    $CRDF
    SEC Filings

    View All

    Cardiff Oncology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update

    8-K - Cardiff Oncology, Inc. (0001213037) (Filer)

    4/2/26 4:15:28 PM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Humacyte Inc.

    10-K - Humacyte, Inc. (0001818382) (Filer)

    3/27/26 4:45:33 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form PRE 14A filed by Precision BioSciences Inc.

    PRE 14A - PRECISION BIOSCIENCES INC (0001357874) (Filer)

    3/27/26 4:05:50 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BMRA
    $BNR
    $CDXS
    $CRDF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Noble Capital Markets initiated coverage on Cardiff Oncology with a new price target

    Noble Capital Markets initiated coverage of Cardiff Oncology with a rating of Outperform and set a new price target of $12.00

    1/5/26 9:06:54 AM ET
    $CRDF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays initiated coverage on Humacyte with a new price target

    Barclays initiated coverage of Humacyte with a rating of Overweight and set a new price target of $3.50

    8/27/25 8:22:05 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leerink Partners initiated coverage on Xilio Therapeutics with a new price target

    Leerink Partners initiated coverage of Xilio Therapeutics with a rating of Outperform and set a new price target of $2.00

    8/6/25 7:25:30 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRA
    $BNR
    $CDXS
    $CRDF
    Leadership Updates

    Live Leadership Updates

    View All

    Humacyte Appoints Rick McElheny as Senior Vice President of Business Development

    - Mr. McElheney brings more than 15 of years' experience in corporate development and alliance management at biopharma companies. -  - He will work with the Company's leadership team to expand corporate collaborations to accelerate the development and commercialization of Humacyte's broad pipeline - DURHAM, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has appointed Rick McElheny to the role of Senior Vice President of Business Development. Mr. McElheny will work with the Company's leadership team to expan

    3/26/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results

    XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 Plan to present new preclinical data at AACR for potential first-in-class masked T cell engager program targeting CLDN18.2 Extended cash runway through the end of 2027 WALTHAM, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced pipeline progress and busin

    3/23/26 7:30:00 AM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BMRA
    $BNR
    $CDXS
    $CRDF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Humacyte Inc.

    SC 13D/A - Humacyte, Inc. (0001818382) (Subject)

    11/20/24 7:10:08 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Humacyte Inc.

    SC 13D/A - Humacyte, Inc. (0001818382) (Subject)

    11/18/24 4:10:14 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.

    SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)

    11/14/24 5:44:28 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BMRA
    $BNR
    $CDXS
    $CRDF
    Financials

    Live finance-specific insights

    View All

    Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026

    DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter and year ended December 31, 2025 on Friday March 27, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update. TitleHumacyte 2025 Fourth Quarter and Year End Financial Results and Corporate UpdateDateMarch 27, 2026Time8:00 a.m. Eastern TimeConference Details1-877-704-4453 (U.S. Investors)1-201-389-0920 (International Investors)1

    3/23/26 8:00:00 AM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results

         Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $37.8 million Technology Transfer Agreement with Merck REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. "Throughout 2025, we made significant strides in demonstrating the importance of our ECO Synthesis

    3/11/26 4:05:00 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

    Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the fourth quarter 2025 and provide a business update on March 12, 2026. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other gene editing technologies in the way it cuts, its smaller size, and its simpler structure. These features are intended for ARCUS nucleases

    3/9/26 4:15:00 PM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care